MacroGenics, Inc. - MGNX STOCK NEWS

MacroGenics, Inc. (NASDAQ: MGNX) announced the appointment of William Heiden as Chair of the Board of Directors effective May 22, 2022, following Paulo F. Costa's term expiration. Heiden brings 35 years of experience in the biotech industry and has a track record of success, including leading AMAG Pharmaceuticals to a $650 million acquisition. The board now includes eight directors, seven of whom are independent. Heiden's expertise is expected to guide MacroGenics' ongoing development of innovative cancer therapies amidst challenging market conditions.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company specializing in antibody-based cancer therapies, has announced its participation in the H.C. Wainwright Global Investment Conference. The event will take place on May 25, 2022, in Miami, FL, where President & CEO Scott Koenig will provide a corporate overview at 11:30 am ET. The company will also conduct one-on-one meetings with investors. A webcast of the presentation will be available on MacroGenics' Investor Relations website for 30 days following the event.

MacroGenics (NASDAQ: MGNX) reported Q1 2022 results, revealing a net loss of $66.4 million, up from $51.3 million in Q1 2021. Revenue declined to $11.1 million from $16.9 million year-over-year. The company is preparing to start a Phase 2/3 prostate cancer study with MGC018 by the end of 2022 and has initiated a Phase 1 study of MGC018 in combination with lorigerlimab for advanced solid tumors. Cash reserves fell to $184 million from $243.6 million, with guidance indicating sufficient funds through 2023 for ongoing projects.

MacroGenics, Inc. (Nasdaq: MGNX) will release its first-quarter 2022 financial results after market close on May 3, 2022. The company will also host a conference call at 4:30 PM ET that same day to discuss the results and recent corporate developments. Interested parties can access the call by dialing (877) 303-6253 for domestic calls or (973) 409-9610 for international calls, using Conference ID# 6791448. A webcast will be available in the Investor Relations section of their website, with a replay accessible for 30 days post-call.

MacroGenics (Nasdaq: MGNX) announced its participation in two investor conferences in March 2022. The first event is the Cowen 42^nd Annual Health Care Conference on March 8, where CEO Scott Koenig will join a panel discussion at 10:30 AM ET. The second is the Barclays Global Healthcare Conference on March 15, featuring a corporate overview at 3:50 PM ET. Both events will include one-on-one meetings and webcasts accessible via MacroGenics' investor relations website, with archived replays available for 30 days.

MacroGenics, Inc. (NASDAQ: MGNX) has promoted Eric Risser to Chief Operating Officer, effective February 22, 2022. Risser has been with the company since 2009, significantly contributing to collaboration partnerships, business development, and program management. He previously served as Senior Vice President and Chief Business Officer. The promotion reflects the company's confidence in his leadership abilities to drive product advancements and shareholder value. MacroGenics focuses on developing innovative antibody-based therapeutics for cancer treatment, leveraging advanced technology platforms.

MacroGenics, Inc. (MGNX) has launched a Phase 1 dose escalation study of MGC018 in combination with lorigerlimab, focusing on B7-H3-directed therapies for treating solid tumors. The company plans to meet the FDA to discuss a registration-directed study for MGC018 in metastatic castration-resistant prostate cancer (mCRPC). Financially, MacroGenics reported $77.4 million in revenue for 2021, a decline from $104.9 million in 2020. The net loss widened to $202.1 million, compared to $129.7 million in the previous year. The company maintains a cash runway through 2023.

MacroGenics, a biopharmaceutical company focused on monoclonal antibody therapeutics for cancer, will release its fourth quarter financial results for 2021 on February 24, 2022, after the market closes. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and corporate progress. Investors can access the call by dialing (877) 303-6253 domestically or (973) 409-9610 internationally, with a Conference ID of 1067087. A webcast will also be available on the company's website.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focusing on monoclonal antibody-based therapies for cancer, will participate in several upcoming virtual conferences in February 2022. Notable events include:

• Guggenheim Healthcare Talks on February 10, 2022, at 9:00 am ET.
• Citi’s 2022 Virtual Immuno-Oncology Summit on February 17, 2022, at 12:30 pm ET.
• 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:40 am ET.

Archived webcasts will be available on MacroGenics' website.